Search Results - "Lasala, Ruggero"

Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability by Lasala, Ruggero, Abrate, Paolo, Zovi, Andrea, Santoleri, Fiorenzo

“…To date, numerous biosimilars are available in Europe and the practice of switching between originator and biosimilar or between two different biosimilars has…”
Get more information

Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials by Lasala, Ruggero, Logreco, Andrea, Romagnoli, Alessia, Santoleri, Fiorenzo, Musicco, Felice, Costantini, Alberto

“…Introduction The European Medicine Agency (EMA) authorizes the marketing of drugs, with the authorization being full, conditional or issued under exceptional…”
Get full text

Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma by Lasala, Ruggero, Santoleri, Fiorenzo, Romagnoli, Alessia, Musicco, Felice, Abrate, Paolo, Costantini, Alberto

“…Introduction Pivotal Randomized Controlled Trials (RCTs) constitute scientific evidence in support of therapeutic choices when a drug is authorized in the…”
Get full text

Available information about paediatric use of onco-haematological drugs authorized by EMA since 2016 by Lasala, Ruggero, Santoleri, Fiorenzo, Zanon, Davide, Romagnoli, Alessia, Abrate, Paolo, Costantini, Alberto, Musicco, Felice

“…Background The treatment options available to children with cancer are limited. This is why for more than 10 years, the European Medicine Agency (EMA) has…”
Get full text

Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice by Santoleri, Fiorenzo, Sorice, Paola, Lasala, Ruggero, Rizzo, Rosa Carmela, Costantini, Alberto

“…The aim of this study is to evaluate adherence and persistence of patients treated with Imatinib, Nilotinib or Dasatinib, also giving economic evaluations on…”
Get full text

Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting by Santoleri, Fiorenzo, Lasala, Ruggero, Ranucci, Elena, Rocchi, Marco, Pulini, Stefano, Morelli, Anna Maria, Spadano, Antonio, Costantini, Alberto

“…Background In combination with dexamethasone, lenalidomide is prescribed in the oral treatment of Multiple Myeloma for patients who have received at least one…”
Get full text

A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions by Musicco, Felice, Lasala, Ruggero, Santoleri, Fiorenzo, Costantini, Alberto, Abrate, Paolo, Carretta, Maria Teresa, Proli, Enrica Maria, Romagnoli, Alessia, Petragnani, Nicola, Vita, Francesco De, Zeuli, Massimo, Vici, Patrizia, Sansone, Massimo, Pasquantonio, Matilde, La Malfa, Antonia, Fulgenzio, Chiara

“…Objective Palbociclib, a highly selective reversible CDK4-6 kinase inhibitor, is indicated in combination with an aromatase inhibitor or in combination with…”
Get full text

Good practices for the development of budget impact models at regional level by Marcellusi, Andrea, Ragonese, Angela, Marinozzi, Andrea, Bortolami, Alberto, Mucherino, Sara, Moreno, Carolina, Antenori, Amalia, Ferrario, Matteo, Simonelli, Claudia, Zanuzzi, Matteo, Cicoira, Marco, Lasala, Ruggero, Russoniello, Francesco, Attanasio, Francesco, Donati, Caterina, Roni, Chiara, Gemmi, Fabrizio, Mennini, Francesco Saverio, Russo, Pierluigi, Scroccaro, Giovanna, Canonico, PierLuigi

“…Introduction: The present work aims to discuss the current scenario of procedures and regulations regarding budget impact analysis/models (BIA/BIM) at regional…”
Get full text

Association between adherence to oral therapies in cancer patients and clinical outcome: A systematic review of the literature by Lasala, Ruggero, Santoleri, Fiorenzo

“…Aims Adherence to therapy is a key factor in successful treatment. The aim of this systematic review is to assess the extent to which patients with better…”
Get full text

EMA approval procedures and assessment of innovation by AIFA: a cross sectional analysis. by Lasala, Ruggero

“…Innovativeness of medicines is a much debated topic: the Italian Medicines Agency (AIFA) has established criteria according to which new medicines are…”
Get more information

Antidepressant deprescribing: State of the art and recommendations—A literature overview by Romagnoli, Alessia, Zovi, Andrea, Santoleri, Fiorenzo, Lasala, Ruggero

“…Introduction In recent years, the consumption of antidepressants has arisen. However, deprescribing antidepressant therapy is very complicated. The aim of this…”
Get full text

Dietary management and access to treatment for patients with glucose deficiency syndrome type 1: an overview review with focus on the European regulatory framework by Zovi, Andrea, Cifani, Carlo, Confalonieri, Corrado, Lasala, Ruggero, Sabbatucci, Michela, Vitiello, Antonio, Vittori, Sauro

“…Glut-1 deficiency Syndrome (GLUT-1 DS) is a rare disease caused by a mutation in the SLC2A1 gene that codes for the glucose transporter protein GLUT-1 DS…”
Get full text

Conflict of interest declarations in published healthcare reports and the need for supportive legislative frameworks: focus on hospital pharmacists' research activity worldwide by Zovi, Andrea, Santoleri, Fiorenzo, Lasala, Ruggero

“…Conflict of interest (COI) encompasses all those circumstances in which a secondary interest can potentially compromise professional actions concerning a…”
Get full text

Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview by Lasala, Ruggero, Zovi, Andrea, Isgrò, Valentina, Romagnoli, Alessia, Musicco, Felice, Santoleri, Fiorenzo

“…Time To Discontinuation (TTD) is defined as the time from the start of treatment to the end of treatment, usually occurring due to loss of efficacy or…”
Get full text

Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies by Vitiello, Antonio, Ferrara, Francesco, Lasala, Ruggero, Zovi, Andrea

“…Many variants of urothelial cancer present diagnostic challenges and carry clinical implications that influence prognosis and treatment decisions. The critical…”
Get full text

Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe by Lasala, Ruggero, Santoleri, Fiorenzo, Romagnoli, Alessia, Musicco, Felice, Costantini, Alberto

“…Purpose The aim of this study was to evaluate in what measure is dosage adjustment particularly prevalent in pivotal clinical trials of oral targeted therapy…”
Get full text

Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia by Santoleri, Fiorenzo, Lasala, Ruggero, Logreco, Andrea, Ranucci, Elena, Costantini, Alberto

“…Purpose The aim of this study was to verify whether the distribution of a treatment diary by a pharmacist could influence the adherence to oral treatment with…”
Get full text

Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of Treatment by Santoleri, Fiorenzo, Lasala, Ruggero, Berardini, Eleononora, Vernacchio, Flavia, Leo, Donato, Costantini, Alberto

“…Background: Adherence and persistence to treatment with disease-modifying therapies (DMTs) is a predictor of the efficacy of treatment. Aims: The objectives of…”
Get full text

Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario by Zovi, Andrea, Lasala, Ruggero, Ferrara, Francesco, Langella, Roberto, Vitiello, Antonio, Sabbatucci, Michela, Musazzi, Umberto Maria

“…Objectives: Migraine is a neurological disease with a high frequency of incidence. The new monoclonal antibodies selective for the calcitonin gene-related…”
Get full text

Anti-CGRP monoclonal antibodies for the preventive treatment of migraine: a cost-effectiveness analysis in the Italian scenario. by Zovi, Andrea, Vitiello, Antonio, Langella, Roberto, Lasala, Ruggero, Ferrara, Francesco

“…Migraine is a neurological disease with a high frequency of incidence. The new monoclonal antibodies anti the calcitonin gene-related peptide ligand (anti-Cgrp…”
Get more information